BCRX
BioCryst Pharmaceuticals, Inc.
12.64
+
0.38
3.10%
18 x 12.01
9 x 12.67
bid
ask
14 @ 04:00 PM
12.08-0.56 (4.43%)
Bearish
28
Bullish
79
sentiment
12.15
day range
12.65
7.61
52 week range
19.99
Prev Close12.26
Open12.28
Low12.15
High12.65
Volume1.95M
Avg. Volume2.61M
Market Cap2.36B
Inst. Own81.18%
Beta1.99
Short Ratio8.40
Div & Yield0.00 /
EPS-1.07
P/E
1yr Target17.60
50day MA13.08
200day MA12.85
^DJI
Dow Jones Industrial Average
33852.50
04:20 PM
+
3.00
0.01%
^IXIC
NASDAQ Composite
10983.80
04:37 PM
-
65.70
0.59%
^GSPC
S&P 500
3957.63
04:20 PM
-
6.31
0.16%
AAPL
141.27
+0.10 (0.07%)
Apple Inc.
141.17
34 @ 04:38 PM
1 x 141.25
1 x 141.27
-
3.05
2.11%
GOOG
95.43
-0.01 (0.01%)
Alphabet Inc.
95.44
2 @ 04:38 PM
2 x 95.35
1 x 95.42
-
0.81
0.84%
AMZN
92.34
-0.08 (0.09%)
Amazon.com, Inc.
92.42
7 @ 04:38 PM
13 x 92.28
14 x 92.30
-
1.53
1.63%
MSFT
240.29
-0.04 (0.02%)
Microsoft Corporation
240.33
12 @ 04:00 PM
11 x 240.44
12 x 240.43
-
1.43
0.59%
BABA
79.81
-0.05 (0.06%)
Alibaba Group Holding Limited
79.86
12 @ 04:01 PM
14 x 0.00
9 x 0.00
+
3.98
5.25%
NFLX
280.84
-0.12 (0.04%)
Netflix, Inc.
280.96
10 @ 04:00 PM
11 x 280.51
9 x 280.63
-
0.21
0.07%
TSLA
180.75
-0.08 (0.04%)
Tesla, Inc.
180.83
12 @ 04:00 PM
12 x 180.83
11 x 180.87
-
2.09
1.14%
NVDA
156.11
-0.28 (0.18%)
NVIDIA Corporation
156.39
25 @ 04:00 PM
40 x 156.45
9 x 156.19
-
1.88
1.19%
AMD
73.31
-0.08 (0.11%)
Advanced Micro Devices, Inc.
73.39
10 @ 04:37 PM
1 x 73.31
1 x 73.35
+
0.20
0.27%
MU
53.75
-1.37 (2.49%)
Micron Technology, Inc.
55.12
19 @ 04:00 PM
29 x 55.10
9 x 55.08
-
0.63
1.13%
SPY
395.34
+0.11 (0.03%)
SPDR S&P 500 ETF Trust
395.23
12 @ 04:00 PM
12 x 395.33
11 x 395.14
-
0.68
0.17%
TQQQ
20.76
-0.01 (0.06%)
ProShares UltraPro QQQ
20.77
385 @ 04:00 PM
400 x 20.72
369 x 20.75
-
0.51
2.40%
BRK-A
460200.00
-15643.00 (3.29%)
Berkshire Hathaway Inc.
475843.00
12 @ 04:04 PM
12 x 0.00
11 x 0.00
+
3131.00
0.66%
| Day Gain | ||
| Gain | ||
| Market Val | ||
| Costs | ||
| Cash | ||
| Portfolio | ||
| Realized | ||
| Dividend |
News
...
| Is BioCryst Pharmaceuticals Inc (BCRX) Stock at the Top of the Biotechnology Industry? | news.google.com • |
| BioCryst Pharmaceuticals Receives Approval for Orladeyo in Israel | news.google.com • |
| BioCryst Pharma (BCRX) Announces Approval of ORLADEYO by the Israeli Ministry of Health | news.google.com • |
| BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Israeli Ministry of Health | news.google.com • |
| 3 Biotechnology stocks under 10 dollars to buy now | thedogofwallstreet.com • |
| BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2022 Earnings Call Transcript | seekingalpha.com • |
Profile
...
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Earning
...
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2022-11-01 | 2022-09 | -0.32 | -0.23 | 0.09 | 28.13% |
| 2022-08-04 | 2022-06 | -0.36 | -0.32 | 0.04 | 11.11% |
| 2022-05-05 | 2022-03 | -0.39 | -0.4 | -0.01 | -2.56% |
| 2022-02-23 | 2021-12 | -0.31 | -0.4 | -0.09 | -29.03% |
| 2021-11-03 | 2021-09 | -0.3 | -0.33 | -0.03 | -10.00% |
| 2021-08-05 | 2021-06 | -0.22 | -0.24 | -0.02 | -9.09% |
Upgrade / Downgrade
...
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2022-11-02 | Evercore ISI Group | Upgrade | In-Line | Outperform |
| 2022-11-02 | RBC Capital | Upgrade | Sector Perform | |
| 2022-08-08 | Oppenheimer | Downgrade | Outperform | Perform |
| 2022-08-05 | Barclays | Upgrade | Equal-Weight | |
| 2022-08-05 | Oppenheimer | Downgrade | Outperform | Perform |
| 2022-08-05 | Evercore ISI Group | Downgrade | Outperform | In-Line |
Insider Holder
...
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2022-06-06 | ABERCROMBIE GEORGE B | Director | 12.87K | Stock Award(Grant) |
| 2022-06-06 | ASELAGE STEPHEN J | Director | 46.59K | Stock Award(Grant) |
| 2022-11-13 | BABU YARLAGADDA S | Officer | 298.54K | Sale |
| 2022-06-06 | GALSON STEVEN K | Director | 12.87K | Stock Award(Grant) |
| 2022-08-30 | HEGGIE THERESA | Director | 30.63K | Stock Award(Grant) |
| 2022-06-06 | HUTSON NANCY J | Director | 77.94K | Stock Award(Grant) |
Institution Ownership
...
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2022-09-29 | Vanguard Group, Inc. (The) | 13.84M | 174.92M | 7.42% |
| 2022-09-29 | Blackrock Inc. | 13.77M | 174.12M | 7.39% |
| 2022-09-29 | Baker Brothers Advisors, LLC | 12.71M | 160.66M | 6.82% |
| 2022-09-29 | State Street Corporation | 9.40M | 118.87M | 5.04% |
| 2022-09-29 | Avoro Capital Advisors LLC | 9.05M | 114.39M | 4.85% |
| 2022-09-29 | FMR, LLC | 5.71M | 72.14M | 3.06% |
Fund Ownership
...
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2022-10-30 | SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 6.07M | 76.67M | 3.25% |
| 2022-06-29 | Vanguard Total Stock Market Index Fund | 5.47M | 69.09M | 2.93% |
| 2022-08-30 | Fidelity Select Portfolios - Biotechnology | 4.35M | 54.95M | 2.33% |
| 2022-08-30 | iShares Russell 2000 ETF | 4.03M | 50.91M | 2.16% |
| 2022-06-29 | Vanguard Extended Market Index Fund | 2.56M | 32.41M | 1.38% |
| 2022-06-29 | Vanguard Small-Cap Index Fund | 2.33M | 29.40M | 1.25% |
Dividend
...
| Dividend | Date |
|---|---|
| 0 | 2014-06-11 |
| 0 | 2014-06-05 |
| 0 | 2014-05-20 |
| 0 | 2014-05-16 |
| 0 | 2014-04-02 |
This topic has been deleted. Only users with topic management privileges can see it.
-
@HT thx for the laugh, needed one today. I’m still a negative nelly here but you made me smile for a bit. 😂
-
Volume can’t even make it to 3 million.
-
Money tied up in a losing stock. It’s painfully obvious.
-
Low Volume. Same chart. No news because they have none. Got duped with dilution of shares.
-
If it was truly a Covid potential don’t you think the Company would do its own PR by now?
-
I might have to take a loss on this do nothing stock, trying to be patient but this is getting really old. Volume today is super low.
-
I don’t know why people think bcrx has a Covid play, if it did it would have been in the news already. No news because they have nothing good to report. Just more of the same ,float around in $4 ish all day, volume of 7 mil , someone here said news guaranteed AH yesterday. Guess not. Fr of mine out once it hits 4.64 , me same at 4.98.
-
I would not recommend this stock to anyone. Low volume, no catalyst, no news. Diluted shares, manipulated, never ending do nothing stock
-
4 million shares is low volume
-
Pleeeease get to 4.98 so I can get out already!
-
Going to be more of the same , this stock seriously is a loser. IMO
-
I want to believe the positive posts in here, but in the end the only news and info has to come from the Company itself which to date is still zilch.
-
Founded 1986 and highest was $6.29.
-
There will be no news because they have none. Only negative financial news.
-
On the wall.
-
Cannot wait to get to my average price and Exit this one. The financial news is not bright and the writing is in the wall.
-
Usbanking news. Zach analysts - $0.28 eps Hope it’s incorrect
-
Toilet Stock. More money will bleed out on Monday. That’s all it ever does. It is not a Covid stock. For myself, huge mistake.
-
Please someone explain the sudden change in volume, in layman’s terms, Tysm
-
Please can someone explain the volume? I’m a newer trader. In layman’s terms. Tysm
-
BioCryst Pharmaceuticals Receives Approval for Orladeyo in Israel
news.google.com • -
3 Biotechnology stocks under 10 dollars to buy now
thedogofwallstreet.com • -
BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2022 Earnings Call Transcript
seekingalpha.com • -
BioCryst to Report Third Quarter 2022 Financial Results on November 1
globenewswire.com • -
3 Biotech Stocks to Buy Now for Extraordinary Gains
investorplace.com • -
Options Bulls Blast Phama Stock on Lifted Clinical Hold
schaeffersresearch.com • -
3 Fast-Growing Stocks to Buy Now
fool.com • -
BioCryst to Report Second Quarter 2022 Financial Results on August 4
globenewswire.com • -
BioCryst to Present at Upcoming Investor Conference
globenewswire.com • -
BioCryst: A Prudent Diversification
seekingalpha.com • -
7 Cheap Biotech Stocks to Buy Now
investorplace.com • -
BioCryst to Present at Upcoming Investor Conferences
globenewswire.com • -
BioCryst to Report First Quarter 2022 Financial Results on May 5
globenewswire.com • -
Why BioCryst Pharmaceuticals Stock Is Falling
benzinga.com • -
BioCryst to Present at Upcoming Investor Conference
globenewswire.com • -
Why BioCryst Pharmaceuticals Stock Is Plunging Today
benzinga.com • -
BioCryst Provides Tremendous Option Value
seekingalpha.com • -
BioCryst: Great Execution, Impressive Pipeline, Long Cash Runway
seekingalpha.com • -
7 Top Growth Stocks to Buy as We Step Into November
investorplace.com • -
BioCryst to Report Third Quarter 2021 Financial Results on November 3
globenewswire.com • -
7 Best Growth Stocks to Buy and Hold for the Next 10 Years
investorplace.com • -
2 Super-Charged Growth Stocks to Buy Now
fool.com • -
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com • -
NICE Recommends BioCryst's Hereditary Angioedema Med
benzinga.com • -
What Wall Street Still Has Wrong. BioCryst To Become Next Rare Disease Giant
seekingalpha.com • -
BioCryst to Present at Upcoming Investor Conferences
globenewswire.com • -
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com • -
BioCryst Appoints Dr. Steven Galson to Board of Directors
globenewswire.com • -
BioCryst Stock Jumps After Pulling Out $200M Equity Raise
benzinga.com • -
BioCryst Withdraws Public Offering
globenewswire.com • -
BioCryst Pharma Stock Heads Higher Thursday: Here's Why
benzinga.com • -
3 Biotech Stocks That Could Rocket Higher
fool.com • -
BioCryst to Report Second Quarter 2021 Financial Results on August 5
globenewswire.com • -
BioCryst Pharmaceuticals - Orladeyo Revenue Will Drive Share Price
seekingalpha.com • -
7 A-Rated Biotech Stocks to Buy Now
investorplace.com • -
BioCryst Pharmaceuticals: An Orphan Disease Innovator With More Upside
seekingalpha.com • -
Is BioCryst a Good Stock to Buy Now?
fool.com • -
BioCryst: Solid Delivery And Follow Through
seekingalpha.com • -
BioCryst to Present at 20th Annual Needham Virtual Healthcare Conference
globenewswire.com • -
BCRX Stock Price: $15 Target By Piper Sandler
pulse2.com • -
BioCryst Technical Levels To Watch
benzinga.com •
